Research / Clinical
Summary
|
|
Diseases/Research Topics
Angiogenesis, Anticancer agents, Chemistry, Synthesis
Dr. Bergdahl's research group is interested in the synthesis of natural products, cytotoxic alkaloids and anticancer agents having specifically angiogenesis inhibitory activities.
Their focus is the syntheses and subsequent evaluation of biologically active target compounds having effects against various forms of cancer, rheumatoid arthritis and infectious diseases.
Azaspirene, a member of the pseurotin family, represents a novel and unique anti-cancer agent, extraordinary in its ability to inhibit angiogenesis. Rather than destroying cancer cells via conventional chemotherapy and radiation, azaspirene turns off blood supply signals sent out by the tumor cells.
Their research is to develop the means to chemically make azaspirene and a library of hybrid pseurotin analogs with potential properties against cancer or arthritis.
This research intertwines development of specifically new methodology in organic synthesis and new strategies toward relevant target molecules, e.g. Streptogramin type antibiotics, Epothilone analogs, and Cytotoxic Alkaloids (Micromide).
Update Summary via ONcLINE (password required)
Click here to request a
new or forgotten password
|
